Queensland Children's Hospital

Queensland Children’s Hospital is a major centre for paediatric cancer care in Australia, providing specialist treatment for children and adolescents from across Queensland and northern New South Wales.

Through a multidisciplinary, family‑centred approach and participation in the ANZCHOG network, the site supports access to clinical trials and contributes to national and international childhood cancer research.

Open Trials

Get Directions

Contact

Recruiting Trials

Open

Not Applicable

Bu4Day-PK-2016

Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study

≤ 18 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital

Haematolymphoid disorders

Open

Not Applicable

CIRCAA

Cancer Information Registry for Children and Adolescents in Australia

No limit

Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours

Open

Phase 2

CONNECT-TarGeT ArmA

Phase II Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT

12 months

39 years

N/A

CNS tumours

Open

Phase 1

CONNECT1903

A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion

≤ 21 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Starship Children’s Hospital

CNS tumours

Open

Phase 2

CONNECT1905

Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent paediatric Adamantinomatous Craniopharyngioma

1 year

39 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital

CNS tumours

Open

Phase 2

CONNECT2108

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent paediatric Adamantinomatous Craniopharyngioma

1 year

39 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital

CNS tumours

Preparing to Open

Phase 2

CONNECT2110

A Phase II Trial of ACT001 in Children and Adolescents with Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

12 months

39 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

Phase 1/2

DART

Phase I/II Trial of Deflexifol for Refractory or Recurrent Paediatric CNS Tumours

12 months

21 years

CNS tumours

Open

Phase 1/2

FaR-RMS (RG_17-247)

An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

No limit

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Westmead Adult Hospital

Soft tissue and bone tumours

Open

Phase 2/3

Glo-BNHL (RG_21-124)

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

≤ 25 years

Queensland Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Haematolymphoid disorders

Open

Phase 1

INTER-EWING-1

International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 (INTER-EWING-1)

>2 years

N/A

Soft tissue and bone tumours

Open

Phase 1

INTER-EWING-1 (RG_21-151)

International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 (INTER-EWING-1)

> 2 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital

Soft tissue and bone tumours

Open

NB-SCI

Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)

< 18 years

Peripheral neuroblastic tumours

Open

Phase 1/2

OPTIMISE Appendix A

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours

1 year

21 years

Open

Phase 1/2

OPTIMISE Appendix C

1 year

21 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital

Preparing to Open

Phase 1/2

PaedNeoVax (ANZCHOG2511)

Multicentre, investigator-initiated phase I/II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study

6 months

25 years

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 1

PNOC019

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)

6 months

25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 2

PNOC022

A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

2 years

39 years

CNS tumours

Open

Phase 2/3

rEECur (RG_13-277)

International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

≥ 2 years (no upper limit)

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital, Sir Charles Gardiner Hospital

Soft tissue and bone tumours

Preparing to Open

Phase 2

SJiMB21

Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

< 60 months

Queensland Children’s Hospital, John Hunter Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

Phase 2

TarGeT-D

Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in paediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations

12 years

39 years

CNS tumours

Preparing to Open

Phase 1

TarGeT-L

A Pilot Study of Lorlatinib for Treatment of Children with Newly Diagnosed High-Grade Glioma with ROS-1 and ALK Fusion

1 year

21 years

CNS tumours

Open

TarGeT-SCR

Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG) – SCREENING PROTOCOL

12 months

39 years

CNS tumours

Preparing to Open

U-R-Immune Glioma

A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients with Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

12 months

25 years

CNS tumours

Open

Phase 1

VICTORY

A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in paediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas

≤ 25 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

ZERO2

Precision Medicine for Every Child With Cancer

< 25 years

Open

Phase 3

AALL1732

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

1 year

25 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Starship Children’s Hospital, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 2

AALL1821

Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients

1 year

31 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Leukaemia / Lymphoma / Blood Disorders

Preparing to Open

Phase 3

AALL2131

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

>1 year

46 years

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 3

AAML1831

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

<21 years

Queensland Children’s Hospital, John Hunter Children’s Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 1/2

ACNS1821

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed paediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

12 months

21 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 2

ACNS2021

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

3 years

29 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 2

ACNS2321

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patient with Central Nervous System Germinomas

3 years

29 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 3

AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk paediatric and Adult Patients with Germ Cell Tumors

Various depending on risk group & consult protocol

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Germ Cell Tumours

Open

Phase 1/2

AMGEN 20180257

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

>12 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 2

ANBL1821

A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma

>1 year

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Neuroblastoma and Ganglioneuroblastoma

Open

Phase 3

ANBL2131

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

<30 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Perth Children’s Hospital, Starship Children’s Hospital

Neuroblastoma and Ganglioneuroblastoma

Open

Phase 2

ANHL2121

Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

189 days

22 years

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 3

ANZUP 1302

Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic Germ Cell Tumours

11 years

50 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital

Germ Cell Tumours

Open

Phase 2/3

AOST2032

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

<40 years

Soft Tissue and Bone Tumours (Sarcoma)

Open

Phase 3

APAL2020D

A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

29 days

21 years

Queensland Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 1/2

APAL2020SC

paediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

<22 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

APEC14B1

Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study

<25 years

Open

Phase 2

AREN1921

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

<30 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Renal and male genital tumours

Open

Phase 3

AREN2231

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

<30 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital

Renal and male genital tumours

Open

Phase 2

ARST1921

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

1 year

18 years

Queensland Children’s Hospital

Soft tissue and bone tumours

Open

Phase 3

ARST2031

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

<50 years

Queensland Children’s Hospital, Children’s Hospital at Westmead

Soft tissue and bone tumours

Open

Phase 2/3

CBYL719P12201

A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in paediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

<100 years

Queensland Children’s Hospital

Soft tissue and bone tumours

Open

Phase 1/2

CO43810

A phase i/ii, open-label, single-arm, two-part trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in paediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma

6 months

30 years

Queensland Children’s Hospital, Perth Children’s Hospital

Haematolymphoid disorders

Open

Phase 1

D0816C00025

A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours

<18 years

Queensland Children’s Hospital, Monash Health Clayton, Children’s Hospital at Westmead

Open

Phase 2

DAY101-001 (FIREFLY)

A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in paediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma

6 months

25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Women’s and Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 3

EFC16295

A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated paediatric Patients <12 Years of Age With Severe Hemophilia A

<11 years

Queensland Children’s Hospital

Haematolymphoid disorders

Open

Phase 2

I3Y-MC-JPEH

Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy

<20 years

Queensland Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 1/2

iMATRIX (GO42286)

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in paediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available

<17 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Open

Phase 1/2

LIGHTBEAM 01A MK-9999-01A

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

6 months

25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital

Haematolymphoid disorders, Peripheral neuroblastic tumours, Soft tissue and bone tumours

Open

Phase 1/2

LIGHTBEAM 01C MK9999-01C

LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruta in paediatric Participants With Relapsed or Refractory Solid Tumors

1 months

17 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital

Open

Phase 3

LTS16294

A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A

No limits

Queensland Children’s Hospital

Haematolymphoid disorders, Peripheral neuroblastic tumours, Soft tissue and bone tumours

Open

Phase 3

ONC201-108

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

No limit

Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital

CNS tumours

Open

Phase 1

P305

Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients

3 months

18 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Royal Children’s Hospital

Haematolymphoid disorders

Open

Phase 3

TAK-620-2004

A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

<17 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital

Haematolymphoid disorders

Open

The CLOCK Trial

Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)

<18 years

Queensland Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital

Open

Phase 1/2

TPX-0005-07

A phase 1/2, open-label safety, tolerability, pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations

<25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

ANZCHOG Hospital Sites

Australia & New Zealand · 11 Sites

About

The peak professional body for childhood cancer across Australia and New Zealand.

Menu

Menu

Considering a clinical trial for a child: A caregiver’s view

Should my child participate in a clinical trial

Menu

Getting to know CoACT in Brain Cancer Awareness Month

Australian Government invests $14 million in ANZCHOG-led childhood brain cancer initiative

Menu

Innovate, Integrate, Inspire: Elevating Supportive Care in Paediatric Haematology and Oncology

Menu

40 Years, 40 People, 40 Questions

Menu

1 SEPT

- 31 SEPT

Better Challenge

Queensland Children's Hospital

Open Trials

Get Directions

Contact

Recruiting Trials

Bu4Day-PK-2016

CIRCAA

CONNECT-TarGeT ArmA

CONNECT1903

CONNECT1905

CONNECT2108

CONNECT2110

DART

FaR-RMS (RG_17-247)

Glo-BNHL (RG_21-124)

INTER-EWING-1

INTER-EWING-1 (RG_21-151)

NB-SCI

OPTIMISE Appendix A

OPTIMISE Appendix C

PaedNeoVax (ANZCHOG2511)

PNOC019

PNOC022

rEECur (RG_13-277)

SJiMB21

TarGeT-D

TarGeT-L

TarGeT-SCR

U-R-Immune Glioma

VICTORY

ZERO2

AALL1732

AALL1821

AALL2131

AAML1831

ACNS1821

ACNS2021

ACNS2321

AGCT1531

AMGEN 20180257

ANBL1821

ANBL2131

ANHL2121

ANZUP 1302

AOST2032

APAL2020D

APAL2020SC

APEC14B1

AREN1921

AREN2231

ARST1921

ARST2031

CBYL719P12201

CO43810

D0816C00025

DAY101-001 (FIREFLY)

EFC16295

I3Y-MC-JPEH

iMATRIX (GO42286)

LIGHTBEAM 01A MK-9999-01A

LIGHTBEAM 01C MK9999-01C

LTS16294

ONC201-108

 Innovate, Integrate, Inspire:   Elevating Supportive Care in Paediatric Haematology and Oncology  